pms-Erlotinib

pms-Erlotinib

erlotinib

Manufacturer:

Pharmascience

Distributor:

T-BOMA
Concise Prescribing Info
Contents
Erlotinib HCl
Indications/Uses
Advanced stage of non-small cell lung cancer (NSCLC) where chemotherapy has not helped to stop disease progression; the disease has not worsened after 4 cycles of 1st line chemotherapy; or activating mutation of the Epidermal Growth Factor Receptor tyrosine kinase (EGFR-TK) is confirmed.
Dosage/Direction for Use
Administration
Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals. If taken w/ medication that reduces stomach acid production: 2 hr before morning dose of medication & 10 hr after evening dose of medication.
Special Precautions
Patients must have a confirmed activating mutation of EGFR-TK prior to starting of therapy. Patients w/ GI ulcers or diverticular disease; cataracts, previous cataract surgery, patients wearing contact lenses; lung disease; patients who smoke tobacco; sugar intolerance. Patients w/ severely reduced liver or kidney function. Avoid pregnancy & breastfeeding while on treatment.
Adverse Reactions
Rash, diarrhea. Tiredness, loss of appetite, difficulty in breathing, cough, infection, nausea, vomiting, mouth irritation, stomach pain, itching, dry skin, eye irritation. Stomach or intestinal bleeding, abnormal blood tests for liver function; headache, dizziness; hair & nail changes; acne or other red or pink little bumps at hair follicles.
Drug Interactions
Potential interaction w/ antifungals (eg, ketoconazole, fluconazole); Ca channel blockers (eg, diltiazem, verapamil); macrolide antibiotics (eg, erythromycin, clarithromycin); fluoroquinolone antibiotics (eg, ciprofloxacin, norfloxacin); other antibiotics eg, rifampin; some antivirals (eg, ritonavir, indinavir); grapefruit juice; St. John's Wort; anticonvulsants eg, carbamazepine, phenytoin; blood thinners eg, warfarin; omeprazole, ranitidine; statins.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EB02 - erlotinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
pms-Erlotinib tab 100 mg
Packing/Price
1 × 10's;3 × 10's
Form
pms-Erlotinib tab 150 mg
Packing/Price
1 × 10's;3 × 10's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in